Akeso Inc., a biopharmaceutical company incorporated in the Cayman Islands, announced on May 24, 2025, the grant of Share Options and Restricted Share Units (RSUs) to recognize the contributions of its directors and existing employees. The announcement, made in compliance with the Listing Rules of the Stock Exchange of Hong Kong, disclosed the allocation of 4,080,000 Share Options to its board members, with Dr. XIA Yu, the chairwoman and executive director, receiving the largest portion of 3,000,000 options. Additionally, 3,035,000 Share Options were distributed among other company employees. The vesting of RSUs will be contingent upon individual performance targets, specifically tailored to the functions of each grantee, such as research and development, sales, and financial performance. This strategic move aims to align the interests of the company's leadership and staff with its operational and growth objectives.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。